Minnesota Clinic Provides Model for Therapeutic Use of Psychedelics

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj Doss notes that there haven’t been many breakthroughs in the psychiatry field in the recent past.

Doss, who is certified in both general and occupational medicine, asserts that a need exists to re-examine how mental illnesses are treated, adding that the treatments used need to be more effective.

This is why he and his co-founder, Kyle Keller, are trying to approach the treatment of various mental health conditions from another perspective. Their clinic, which is located in Minnesota, provides psychedelics as a part of mental health treatment.

However, Keller notes, while conventional treatments such as psychotropic drugs and talk therapy have helped individuals across the globe, these treatments have their limitations. Keller adds that staff members at IIT view the use of psychedelic drugs as a promising new way to assist patients in making progress when they’re stuck in their mental health, allowing them to move forward on their recovery journeys.

Psychedelics, he notes, used in conjunction with psychotherapy can assist patients to process their trauma and treat their mental health more effectively.

Presently, their clinic provides ketamine treatments to their patients. Ketamine, which is commonly used an as anesthetic, has shown potential in managing chronic depression and is being provided at infusion centers and clinics across the country.

Keller and Doss plan to expand the clinic’s treatment options to include other psychedelics, such as psilocybin mushrooms and MDMA, which is commonly referred to as molly or ecstasy. Both substances have shown potential in treating common mental conditions, such as post-traumatic stress disorder, anxiety and depression. However, this plan is dependent on the FDA’s approval.

Keller asserts that they are laying the foundation to offer other psychedelic-assisted therapies as soon as they become available. He adds that individuals who are well suited to psychedelic therapy include those who feel a sense of meaninglessness, as if nothing matters. He explained that often psychedelics create a profound sense of meaning for people, enabling them to move forward with their lives when otherwise they may not be able to.  Other individuals who would benefit from psychedelic therapy are those with a terminal diagnosis.

Keller maintains that both he and Doss are focused on progress. Their objective, he adds, is to help patients move forward in their healing journeys. This is in addition to finding new ways to make their treatments more accessible.

The preparations that the IIT team are undertaking in anticipation that more psychedelics will soon be approved for use isn’t altogether farfetched when considering how rapidly different companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are moving forward in their efforts to develop and commercialize psychedelic drug formulations.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050